JP2017513477A - ゲノムｄｎａを改変するための方法および組成物 - Google Patents

ゲノムｄｎａを改変するための方法および組成物 Download PDF

Info

Publication number
JP2017513477A
JP2017513477A JP2016562503A JP2016562503A JP2017513477A JP 2017513477 A JP2017513477 A JP 2017513477A JP 2016562503 A JP2016562503 A JP 2016562503A JP 2016562503 A JP2016562503 A JP 2016562503A JP 2017513477 A JP2017513477 A JP 2017513477A
Authority
JP
Japan
Prior art keywords
cell
cells
dna
sequence
electroporation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016562503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513477A5 (enExample
Inventor
リンホン リー
リンホン リー
マドゥスーダン ペーシュワー
マドゥスーダン ペーシュワー
Original Assignee
マックスサイト インコーポレーティッド
マックスサイト インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックスサイト インコーポレーティッド, マックスサイト インコーポレーティッド filed Critical マックスサイト インコーポレーティッド
Publication of JP2017513477A publication Critical patent/JP2017513477A/ja
Publication of JP2017513477A5 publication Critical patent/JP2017513477A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016562503A 2014-04-14 2015-04-13 ゲノムｄｎａを改変するための方法および組成物 Pending JP2017513477A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461979178P 2014-04-14 2014-04-14
US61/979,178 2014-04-14
US201462078706P 2014-11-12 2014-11-12
US62/078,706 2014-11-12
PCT/US2015/025523 WO2015160683A1 (en) 2014-04-14 2015-04-13 Methods and compositions for modifying genomic dna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020127917A Division JP7209671B2 (ja) 2014-04-14 2020-07-29 ゲノムｄｎａを改変するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2017513477A true JP2017513477A (ja) 2017-06-01
JP2017513477A5 JP2017513477A5 (enExample) 2018-05-24

Family

ID=54324457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016562503A Pending JP2017513477A (ja) 2014-04-14 2015-04-13 ゲノムｄｎａを改変するための方法および組成物
JP2020127917A Active JP7209671B2 (ja) 2014-04-14 2020-07-29 ゲノムｄｎａを改変するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020127917A Active JP7209671B2 (ja) 2014-04-14 2020-07-29 ゲノムｄｎａを改変するための方法および組成物

Country Status (8)

Country Link
US (1) US20170029805A1 (enExample)
EP (1) EP3132025B1 (enExample)
JP (2) JP2017513477A (enExample)
KR (1) KR102406585B1 (enExample)
CN (1) CN106687585B (enExample)
ES (1) ES2962509T3 (enExample)
SG (1) SG11201608503UA (enExample)
WO (1) WO2015160683A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP2970915B1 (en) 2013-03-15 2019-08-14 Maxcyte, Inc. Methods and compositions for generating stable transfected cells
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
KR20230054509A (ko) 2013-11-07 2023-04-24 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
CN106460003A (zh) 2014-04-08 2017-02-22 北卡罗来纳州立大学 用于使用crispr相关基因rna引导阻遏转录的方法和组合物
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
KR20170135966A (ko) 2015-04-13 2017-12-08 맥스시티 인코포레이티드 게놈 dna를 변형시키기 위한 방법 및 조성물
EP3303607A4 (en) 2015-05-29 2018-10-10 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
CN107922918B (zh) 2015-06-15 2022-10-21 北卡罗来纳州立大学 用于有效递送核酸和基于rna的抗微生物剂的方法和组合物
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
JP2019520844A (ja) * 2016-07-21 2019-07-25 マックスサイト インコーポレーティッド ゲノムｄｎａを改変するための方法および組成物
WO2018022930A1 (en) * 2016-07-27 2018-02-01 The Board Of Trustees Of The Leland Stanford Junior University Immolative cell-penetrating complexes for nucleic acid delivery
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018232382A1 (en) * 2017-06-16 2018-12-20 Applied Stemcell, Inc. Gene editing methods with increased knock-in efficiency
KR102424850B1 (ko) 2017-06-30 2022-07-22 인스크립타 인코포레이티드 자동 세포 처리 방법, 모듈, 기기 및 시스템
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018338990B2 (en) 2017-09-30 2022-06-23 Inscripta, Inc. Flow through electroporation instrumentation
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
US11739322B2 (en) 2018-02-01 2023-08-29 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Method for genome editing using a self-inactivating CRISPR nuclease
EP3775159A4 (en) 2018-03-29 2022-01-19 Inscripta, Inc. AUTOMATED REGULATION OF CELL GROWTH RATES FOR INDUCTION AND TRANSFORMATION
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020081149A2 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University Recombinant type i crispr-cas system
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12338453B2 (en) 2018-12-17 2025-06-24 Consejo Superior De Investigaciones Científicas (Csic) Method for the introduction of genetic information in cell by site-specific integration system
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2021154706A1 (en) 2020-01-27 2021-08-05 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138877A1 (en) * 2001-08-22 2008-06-12 Dzekunov Sergey M Apparatus and Method For Electroporation of Biological Samples
WO2012012738A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
US20130122591A1 (en) * 2011-10-27 2013-05-16 The Regents Of The University Of California Methods and compositions for modification of the hprt locus
WO2013188522A2 (en) * 2012-06-12 2013-12-19 Genentech, Inc. Methods and compositions for generating conditional knock-out alleles
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
JP2016514454A (ja) * 2013-03-15 2016-05-23 マックスサイト インコーポレーティッド 安定なトランスフェクトされた細胞を生成するための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289104A1 (en) * 2000-09-15 2002-03-26 Deltagen, Inc. Methods of producing cells and animals comprising targeted gene modifications
WO2007030674A2 (en) * 2005-09-07 2007-03-15 Maxcyte, Inc. Use of nucleases to improve viability and enhance transgene expression in transfected cells
KR101087809B1 (ko) * 2006-04-10 2011-11-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단일 세포 및 콜로니의 수집을 위한 시스템
CA2687688C (en) * 2007-05-23 2017-03-28 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression in t cells
WO2013139994A1 (en) * 2012-03-23 2013-09-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) A novel method of producing an oocyte carrying a modified target sequence in its genome
BR112014027813A2 (pt) * 2012-05-07 2017-08-08 Dow Agrosciences Llc métodos e composições para integração de transgenes direcionada mediada por nuclease
CN102839214A (zh) * 2012-09-06 2012-12-26 许汉鹏 筛选真核细胞基因组内特定基因调控相关机制和分子的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138877A1 (en) * 2001-08-22 2008-06-12 Dzekunov Sergey M Apparatus and Method For Electroporation of Biological Samples
WO2012012738A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
US20130122591A1 (en) * 2011-10-27 2013-05-16 The Regents Of The University Of California Methods and compositions for modification of the hprt locus
WO2013188522A2 (en) * 2012-06-12 2013-12-19 Genentech, Inc. Methods and compositions for generating conditional knock-out alleles
JP2016514454A (ja) * 2013-03-15 2016-05-23 マックスサイト インコーポレーティッド 安定なトランスフェクトされた細胞を生成するための方法および組成物
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BERDIEN B. ET AL., GENE THERAPY, vol. 21[Epub 2014 Mar 27], JPN6019017319, pages 539 - 548, ISSN: 0004034594 *
CANNON P. M. ET AL.: "183. Electroporation of ZFN mRNA Enables Efficient CCR5 Gene Disruption in Mobilized Blood Hematopoi", MOLECULAR THERAPY, vol. Vol.21, Supplement 1 (2013), JPN6020012073, pages 71 - 72, ISSN: 0004242845 *
LI L. ET AL., METHODS IN MOLECULAR BIOLOGY, vol. Vol.969 (2013), JPN6019017324, pages 127 - 138, ISSN: 0004242841 *
LI L. ET AL., MOLECULAR THERAPY, vol. Vol.22 Suppl 1(2014 May), JPN6019017320, pages 278 - 721, ISSN: 0004034593 *
LI L. ET AL., TECHNOLOGY IN CANCER RESEARCH & TREATMENT, vol. vol.1 No.5 (2002), JPN6019017325, pages 341 - 349, ISSN: 0004242842 *
LI L. ET AL.: "cGMP-compliant, clinical scale, non-viral platform for efficient gene editing using CRISPR/Cas9.", JOURNAL OF CELL THERAPY, SUPPLEMENT TO: CYTOTHERAPY, ISCT 2014 ANNUAL MEETING ABSTRACTS, vol. Vol.16 Number 4S (2014 Apr), JPN6019017322, pages 37 - 111, ISSN: 0004034592 *
RAN F. ET AL., NATURE PROTOCOLS, vol. Vol.8 No.11 (2013), JPN6019017323, pages 2281 - 2308, ISSN: 0004242840 *
WANG H. ET AL., CELL, vol. Vol.153(2013), JPN6018025896, pages 910 - 918, ISSN: 0004242844 *
WATANABE M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 402(2010), JPN6019017321, pages 14 - 18, ISSN: 0004034595 *
YANG L. ET AL., NUCLEIC ACIDS RESEARCH, vol. Vol.41, No.19 (2013), JPN6020012076, pages 9049 - 9061, ISSN: 0004242846 *
ZHAO Y. ET AL., MOLECULAR THERAPY, vol. Vol.13 No.1 (2006), JPN6019017326, pages 151 - 159, ISSN: 0004242843 *

Also Published As

Publication number Publication date
US20170029805A1 (en) 2017-02-02
EP3132025B1 (en) 2023-08-30
EP3132025A1 (en) 2017-02-22
CN106687585A (zh) 2017-05-17
SG11201608503UA (en) 2016-11-29
CN106687585B (zh) 2021-11-02
KR20170026332A (ko) 2017-03-08
ES2962509T3 (es) 2024-03-19
WO2015160683A1 (en) 2015-10-22
JP7209671B2 (ja) 2023-01-20
KR102406585B1 (ko) 2022-06-07
JP2021010366A (ja) 2021-02-04
EP3132025A4 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
JP7209671B2 (ja) ゲノムｄｎａを改変するための方法および組成物
JP2022153470A (ja) ゲノムｄｎａを改変するための方法および組成物
JP6885876B2 (ja) ゲノムｄｎａを改変するための方法および組成物
US12130281B2 (en) Gene editing through microfluidic delivery
WO2018071663A1 (en) Rna compositions for genome editing
US20250115903A1 (en) Compositions and methods for editing genomes
EP4433585A2 (en) Novel omni crispr nucleases
WO2022251217A2 (en) Ciita targeting zinc finger nucleases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200330